• Something wrong with this record ?

Cardiac troponins--Translational biomarkers in cardiology: Theory and practice of cardiac troponin high-sensitivity assays

M. Adamcova, O. Popelova-Lencova, E. Jirkovsky, F. Simko, V. Gersl, M. Sterba,

. 2016 ; 42 (2) : 133-48. [pub] 20160215

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't, Review

Persistent link   https://www.medvik.cz/link/bmc17000475

Tn is a unique translational biomarker in cardiology whose potential has not been diminished in the new era of high sensitive assays. cTns can be valuable markers in cardiac diseases as well as in infectious diseases and respiratory diseases. Furthermore, the role of cTns is growing in the routine evaluation of cardioxicity and in determining the efficacy/safety ratio of novel cardioprotective strategies in clinical settings. cTns can detect myocardial injury not only in a wide spectrum of laboratory animals in experimental studies in vivo, but also in isolated heart models or cardiomyocytes in vitro. The crucial issue regarding the cross-species usage of cardiac troponin investigation remains the choice of cardiac troponin testing. This review summarizes the recent proteomic data on aminoacid sequences of cTnT and cTnI in various species, as well as selected analytical characteristics of human cardiac troponin high-sensitivity assays. Due to the highly phylogenetically conserved structure of troponins, the same bioindicator can be investigated using the same method in both clinical and experimental cardiology, thus contributing to a better understanding of the pathogenesis of cardiac diseases as well as to increased effectiveness of troponin use in clinical practice. Measuring cardiac troponins using commercially available human high-sensitivity cardiac troponin tests with convenient antibodies selected on the basis of adequate proteomic knowledge can solve many issues which would otherwise be difficult to address in clinical settings for various ethical and practical reasons. Our survey could help elaborate the practical guidelines for optimizing the choice of cTns assay in cardiology.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc17000475
003      
CZ-PrNML
005      
20170113112438.0
007      
ta
008      
170103s2016 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1002/biof.1261 $2 doi
024    7_
$a 10.1002/biof.1261 $2 doi
035    __
$a (PubMed)26876101
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Adamcova, Michaela $u Department of Physiology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, 500 38, Czech Republic. $7 gn_A_00001180
245    10
$a Cardiac troponins--Translational biomarkers in cardiology: Theory and practice of cardiac troponin high-sensitivity assays / $c M. Adamcova, O. Popelova-Lencova, E. Jirkovsky, F. Simko, V. Gersl, M. Sterba,
520    9_
$a Tn is a unique translational biomarker in cardiology whose potential has not been diminished in the new era of high sensitive assays. cTns can be valuable markers in cardiac diseases as well as in infectious diseases and respiratory diseases. Furthermore, the role of cTns is growing in the routine evaluation of cardioxicity and in determining the efficacy/safety ratio of novel cardioprotective strategies in clinical settings. cTns can detect myocardial injury not only in a wide spectrum of laboratory animals in experimental studies in vivo, but also in isolated heart models or cardiomyocytes in vitro. The crucial issue regarding the cross-species usage of cardiac troponin investigation remains the choice of cardiac troponin testing. This review summarizes the recent proteomic data on aminoacid sequences of cTnT and cTnI in various species, as well as selected analytical characteristics of human cardiac troponin high-sensitivity assays. Due to the highly phylogenetically conserved structure of troponins, the same bioindicator can be investigated using the same method in both clinical and experimental cardiology, thus contributing to a better understanding of the pathogenesis of cardiac diseases as well as to increased effectiveness of troponin use in clinical practice. Measuring cardiac troponins using commercially available human high-sensitivity cardiac troponin tests with convenient antibodies selected on the basis of adequate proteomic knowledge can solve many issues which would otherwise be difficult to address in clinical settings for various ethical and practical reasons. Our survey could help elaborate the practical guidelines for optimizing the choice of cTns assay in cardiology.
650    _2
$a biotest $x metody $7 D001681
650    _2
$a biologické markery $x metabolismus $7 D015415
650    _2
$a nemoci srdce $x diagnóza $x metabolismus $x patologie $7 D006331
650    _2
$a lidé $7 D006801
650    _2
$a myokard $x metabolismus $x patologie $7 D009206
650    _2
$a proteomika $7 D040901
650    _2
$a troponin I $x izolace a purifikace $x metabolismus $7 D019210
650    _2
$a troponin T $x izolace a purifikace $x metabolismus $7 D020107
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
655    _2
$a přehledy $7 D016454
700    1_
$a Popelova-Lencova, Olga $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, 500 38, Czech Republic.
700    1_
$a Jirkovsky, Eduard $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, 500 38, Czech Republic.
700    1_
$a Simko, Fedor $u Institute of Pathological Physiology, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic - Sasinkova 4, 811 08 Bratislava, Slovak Republic. 3rdDepartment of Internal Medicine, Faculty of Medicine, Comenius University, Bratislava, Slovak Republic - Limbova 5, 833 05, Bratislava, Slovak Republic. Institute of Experimental Endocrinology, Slovak Academy of Sciences, Bratislava, Slovak Republic - Vlarska 3, 833 06, Bratislava, Slovak Republic. Center of Excellence NOREG, Slovak Republic.
700    1_
$a Gersl, Vladimir $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, 500 38, Czech Republic.
700    1_
$a Sterba, Martin $u Department of Pharmacology, Faculty of Medicine in Hradec Kralove, Charles University in Prague, Hradec Kralove, 500 38, Czech Republic.
773    0_
$w MED00006013 $t BioFactors (Oxford, England) $x 1872-8081 $g Roč. 42, č. 2 (2016), s. 133-48
856    41
$u https://pubmed.ncbi.nlm.nih.gov/26876101 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20170103 $b ABA008
991    __
$a 20170113112539 $b ABA008
999    __
$a ok $b bmc $g 1179615 $s 961042
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 42 $c 2 $d 133-48 $e 20160215 $i 1872-8081 $m BioFctors $n Biofactors $x MED00006013
LZP    __
$a Pubmed-20170103

Find record

Citation metrics

Archiving options